WallStSmart

Intelligent Bio Solutions Inc. (INBS)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 990713% more annual revenue ($35.48B vs $3.58M). MDT leads profitability with a 13.0% profit margin vs 0.0%. MDT earns a higher WallStSmart Score of 56/100 (C).

INBS

Hold

40

out of 100

Grade: D

Growth: 6.3Profit: 2.5Value: 5.0Quality: 5.0

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for INBS.

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INBS2 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
47.6%10/10

Revenue surging 47.6% year-over-year

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

INBS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.50M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-1.5%2/10

ROE of -1.5% — below average capital efficiency

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : INBS

The strongest argument for INBS centers on Price/Book, Revenue Growth. Revenue growth of 47.6% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : INBS

The primary concerns for INBS are EPS Growth, Market Cap, Profit Margin.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

INBS profiles as a hypergrowth stock while MDT is a value play — different risk/reward profiles.

INBS carries more volatility with a beta of 4.63 — expect wider price swings.

INBS is growing revenue faster at 47.6% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 40/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Intelligent Bio Solutions Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Intelligent Bio Solutions Inc. (INBS) is a forward-thinking biotechnology company committed to revolutionizing healthcare through the development of innovative diagnostic solutions and biomarker-driven technologies, especially in the realm of drug abuse testing and monitoring. Leveraging cutting-edge scientific advancements, the company aims to enhance healthcare outcomes by offering highly accurate and rapid-testing methodologies that facilitate timely clinical decision-making. Positioned strategically at the nexus of technology and healthcare, INBS is well-positioned to capitalize on the growing demand for advanced diagnostic tools in a dynamic market landscape.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?